{"ok":true,"entity":{"id":"united-therapeutics","name":"United Therapeutics","entityType":"company","officialName":"United Therapeutics Corporation","canonicalName":"United Therapeutics","displayName":"United Therapeutics","category":"バイオ医薬企業（肺高血圧症治療薬・臓器製造）","shortDescription":"United Therapeutics Corporation（Nasdaq: UTHR）は米メリーランド州シルバースプリングに事業所を置く公益法人（public benefit corporation）形態のバイオ医薬企業で、TyvasoやRemodulinなどを販売し、異種移植用臓器などの臓器供給に関する開発も進めている。2026年8月5日発表の2026年第2四半期の総収益は7億8,330万米ドルで、2026年7月にはThymmune Therapeuticsの買収が完了したと報じられた。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.unither.com/","updatedAt":"2026-10-29T04:31:31.488Z","secondaryClusters":[],"alias":["United Therapeutics Corporation","ユナイテッド・セラピューティクス"],"searchKeywords":["ユナイテッド・セラピューティクス","United Therapeutics","UTHR","Tyvaso","Remodulin","UThymoKidney","Thymmune","臓器製造","異種移植","public benefit corporation"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}